CLAIMS

1. A pharmaceutical composition for preventing or treating respiratory infection comprising a pharmaceutically acceptable carrier and at least one (*e.g.*, two, three, four) active (*e.g.*, antimicrobial and/or antiviral) agents selected from lactoferrin (*e.g.*, apolactoferrin, etc.), lysozyme, ICAM-1 (*e.g.*, soluble ICAM-1, etc.), sialic acid (*e.g.*, sialyllactose, etc.), and a neuraminidase inhibitor (*e.g.*, quercetin, isoquercetin, etc.).

2. The pharmaceutical composition according to claim 1, comprising sialic acid.

3. The pharmaceutical composition according to claim 2, wherein sialic acid is the sole active agent.

4. The pharmaceutical composition according to claim 1, comprising a neuraminidase inhibitor.

5. The pharmaceutical composition according to claim 4, wherein said neuraminidase inhibitor is the sole active agent.

6. The pharmaceutical composition according to claim 1, comprising lactoferrin.

7. The pharmaceutical composition according to claim 6, wherein said lactoferrin is the sole active agent.

8. The pharmaceutical composition according to claim 1, wherein said composition comprises at least two (*e.g.*, two, three, four) active agents selected from lactoferrin (*e.g.*, apolactoferrin, etc.), lysozyme, ICAM-1 (*e.g.*, soluble ICAM-1, etc.), sialic acid (*e.g.*, sialyllactose, etc.), and a neuraminidase inhibitor (*e.g.*, quercetin, isoquercetin, etc.).

9. The pharmaceutical composition according to claim 8 comprising lactoferrin and soluble ICAM-1.

10. The pharmaceutical composition according to claim 9, wherein said lactoferrin and soluble ICAM-1 are the sole active agents.

11. The pharmaceutical composition according to claim 8 comprising lysozyme and soluble ICAM-1.

12. The pharmaceutical composition according to claim 11, wherein said lysozyme and soluble ICAM-1 are the sole active agents.

13. The pharmaceutical composition according to claim 8 comprising lactoferrin, lysozyme, and soluble ICAM-1.

14. The pharmaceutical composition according to claim 13, wherein said lactoferrin, lysozyme, and soluble ICAM-1 are the sole active agents.

15. The pharmaceutical composition according to claim 8 comprising lactoferrin and lysozyme.

16. The pharmaceutical composition according to claim 15, wherein said lactoferrin and said lysozyme are the sole active agents.

17. The pharmaceutical composition according to claim 8 comprising lactoferrin and sialic acid.

18. The pharmaceutical composition according to claim 17, wherein said lactoferrin and said sialic acid are the sole active agents.

19. The pharmaceutical composition according to claim 8 comprising lactoferrin, lysozyme, and sialic acid.

20. The pharmaceutical composition according to claim 19, wherein said lactoferrin, said lysozyme, and said sialic acid are the sole active agents.

21. The pharmaceutical composition according to claim 8 comprising lactoferrin, lysozyme, sialic acid, and a neuraminidase inhibitor.

22. The pharmaceutical composition according to claim 21, wherein said lactoferrin, said lysozyme, said sialic acid, and said neuraminidase inhibitor are the sole active agents.

23. The pharmaceutical composition according to claim 8 comprising sialic acid and a neuraminidase inhibitor.

24. The pharmaceutical composition according to claim 23, wherein said sialic acid and said neuraminidase inhibitor are the sole active agents.

25. The pharmaceutical composition according to claim 1, wherein said composition comprises a neuraminidase inhibitor and said neuraminidase inhibitor is quercetin or isoforms thereof.

26. The pharmaceutical composition according to claim 1, further comprising one or more of zinc peroxide, copper, and silver.

27. The pharmaceutical composition according to claim 1, further comprising carrageenan.

28. The pharmaceutical composition according to claim 1, further comprising one or more ingredients selected from the group consisting of marshmallow extract, calendula extract, citrus peel extract, honey extract, rosemary extract, myrrh extract, Helichrysum extract, arrowroot extract, neem oil, vitamin C, vitamin E, and grapefruit seed extract.

29. The pharmaceutical composition according to claim 1, further comprising citrus peel extract (*e.g.*, lemon peel extract).

30. The pharmaceutical composition according to claim 1, wherein said composition is in the form of a nasal spray, nasal drops, oral spray, oral rinse, or lozenge.

31. A pharmaceutical composition comprising quercetin and isoforms thereof (*e.g.*, quercetin, etc.) and one or more active agents selected from lactoferrin (*e.g.*, apolactoferrin, etc.), lysozyme, ICAM-1 (*e.g.*, soluble ICAM-1, etc.), sialic acid (*e.g.*, sialyllactose, etc.).

32. The pharmaceutical composition according to claim 31 comprising isoquercetin, lactoferrin, lysozyme, and sialic acid.

33. The pharmaceutical composition according to claim 31, wherein said lactoferrin, said lysozyme, said sialic acid, and said isoquercetin are the sole active agents.

34. The pharmaceutical composition according to claim 31 comprising sialic acid and isoquercetin.

35. The pharmaceutical composition according to claim 31, wherein said sialic acid and isoquercetin are the sole active agents.

36. Use of the composition of claim 1 in the manufacture of a medicament for prophylaxis and/or treatment of human rhinovirus infection, wherein the composition is to be administered to the nasal and/or oral mucosa of an individual in need thereof.

37. The use according to claim 36, wherein the nasal and/or oral mucosa of said individual in need thereof has human rhinovirus in contact therewith.

38. Use of the composition of claim 1 in the manufacture of a medicament for the prophylaxis and/or treatment of human influenza virus infection, wherein the composition is to be administered to the nasal and/or oral mucosa of an individual in need thereof.

39. The use according to claim 38, wherein the nasal and/or oral mucosa of said individual in need thereof has human influenza virus in contact therewith.